Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Life Sciences Industry Analysis

UpdatedAug 01, 2026
DataAggregated Company Financials
Companies22
  • 7D7.1%
  • 3M16.4%
  • 1Y14.0%
  • YTD19.1%

In the last week, the Life Sciences industry is up 7.1%, with Divi's Laboratories up 11%. In the same time, Syngene International was down 5.1%. This means that the industry has gained 14% over the past year. As for the next few years, earnings are expected to grow by 22% per annum.

Industry Valuation and Performance

Has the Indian Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 02 Aug 2026₹3.7t₹360.6b₹45.6b40.1x81x10.3x
Tue, 30 Jun 2026₹3.3t₹361.8b₹46.4b42.6x70.4x9x
Thu, 28 May 2026₹3.3t₹362.1b₹46.1b32x71.4x9.1x
Sat, 25 Apr 2026₹3.1t₹350.2b₹46.2b31.2x67x8.8x
Mon, 23 Mar 2026₹2.9t₹350.2b₹46.2b28.9x62.2x8.2x
Wed, 18 Feb 2026₹2.9t₹350.2b₹46.2b29.4x63.3x8.4x
Fri, 16 Jan 2026₹3.1t₹342.6b₹48.4b31.2x63.4x9x
Sun, 14 Dec 2025₹3.1t₹342.6b₹48.4b33.2x64.6x9.1x
Tue, 11 Nov 2025₹3.2t₹338.6b₹47.8b39.3x67.4x9.5x
Thu, 09 Oct 2025₹3.1t₹331.4b₹45.5b46.3x68.8x9.4x
Sat, 06 Sep 2025₹3.2t₹331.4b₹45.5b50.9x69.5x9.6x
Mon, 04 Aug 2025₹3.2t₹321.1b₹42.2b52.8x76.4x10x
Wed, 02 Jul 2025₹2.9t₹300.7b₹37.4b45x78.5x9.7x
Fri, 30 May 2025₹2.8t₹299.9b₹37.1b46.2x76.2x9.4x
Sun, 27 Apr 2025₹2.6t₹288.4b₹30.7b47.6x84.3x9x
Tue, 25 Mar 2025₹2.6t₹287.4b₹30.8b48.1x85x9.1x
Thu, 20 Feb 2025₹2.5t₹287.4b₹30.8b47.4x81.7x8.7x
Sat, 18 Jan 2025₹2.5t₹269.1b₹30.1b50.9x83.6x9.3x
Mon, 16 Dec 2024₹2.4t₹254.2b₹28.8b50.8x82.1x9.3x
Wed, 13 Nov 2024₹2.4t₹253.2b₹27.8b46.1x84.7x9.3x
Fri, 11 Oct 2024₹2.4t₹247.6b₹26.3b50.3x91.6x9.7x
Sun, 08 Sep 2024₹2.2t₹247.6b₹26.3b50.2x84x8.9x
Tue, 06 Aug 2024₹1.9t₹205.8b₹24.7b36.2x76.8x9.2x
Thu, 04 Jul 2024₹1.8t₹198.0b₹23.7b33.4x74.1x8.9x
Sat, 01 Jun 2024₹1.7t₹195.1b₹21.6b31.8x76.4x8.5x
Mon, 29 Apr 2024₹1.5t₹167.8b₹18.7b30.8x79.5x8.9x
Wed, 27 Mar 2024₹1.3t₹168.5b₹18.6b28.1x70.5x7.8x
Fri, 23 Feb 2024₹1.4t₹168.5b₹18.6b31.3x75.9x8.4x
Sun, 21 Jan 2024₹1.4t₹165.9b₹18.9b31.6x74.2x8.4x
Tue, 19 Dec 2023₹1.4t₹155.9b₹18.1b21.7x75.3x8.7x
Thu, 16 Nov 2023₹1.3t₹156.5b₹18.1b22x73x8.4x
Sat, 14 Oct 2023₹1.4t₹154.7b₹19.7b25.7x70.9x9x
Mon, 11 Sep 2023₹1.4t₹154.7b₹19.7b26.6x71.7x9.1x
Wed, 09 Aug 2023₹1.4t₹158.1b₹23.2b30.5x62.1x9.1x
Price to Earnings Ratio

62.1x


Total Market Cap: ₹1.4tTotal Earnings: ₹23.2bTotal Revenue: ₹158.1bTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Life Sciences Industry Price to Earnings3Y Average 74.7x202420252026
Current Industry PE
  • Investors are optimistic on the Indian Life Sciences industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 81.0x which is higher than its 3-year average PE of 74.6x.
  • The 3-year average PS ratio of 9.0x is lower than the industry's current PS ratio of 10.3x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 25% per year over the last three years.
  • Revenues for these companies have grown 32% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Indian Healthcare industry?

IN Market2.00%
Healthcare2.68%
Life Sciences7.08%
Clinical Research and Equipment7.08%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
DIVISLAB Divi's Laboratories₹8.06k11.1%
+₹214.4b		26.6%PE83.3x
ANTHEM Anthem Biosciences₹809.205.1%
+₹22.1b		9.6%PE79.1x
SAILIFE Sai Life Sciences₹1.32k6.7%
+₹17.4b		66.9%PE79.9x
INDGN Indegene₹515.154.6%
+₹5.4b		-10.8%PE31x
524394 Vimta Labs₹608.156.6%
+₹1.7b		-11.7%PE34.1x

Latest News

530239
₹307.10
Suven Life Sciences
7D
-2.9%
1Y
15.3%
SYNGENE
₹385.90
Syngene International
7D
-5.1%
1Y
-45.1%
Narrative Update • Jul 30

SYNGENE: Leadership Transition And Subsidiary Exit Will Support Future Earnings

Analysts have trimmed their price target on Syngene International to ₹541.25 from ₹578.13, reflecting updated assumptions on revenue growth, profit margin and future P/E expectations. What’s in the News for Syngene International Board meeting scheduled on July 29, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter ending June 30, 2026, among other routine matters.
INDGN
₹515.15
Indegene
7D
4.6%
1Y
-10.8%
ONESOURCE
₹1,619.70
OneSource Specialty Pharma
7D
-2.1%
1Y
-12.7%
Analysis Article • Jul 29

Analysts Are Updating Their OneSource Specialty Pharma Limited (NSE:ONESOURCE) Estimates After Its First-Quarter Results

It's been a good week for OneSource Specialty Pharma Limited ( NSE:ONESOURCE ) shareholders, because the company has...
ANTHEM
₹809.20
Anthem Biosciences
7D
5.1%
1Y
9.6%
New Narrative • Jul 28

Capacity Expansion And Modalities Shift Will Support Stronger Long-Term Earnings Visibility

Catalysts About Anthem Biosciences Anthem Biosciences is a contract research, development and manufacturing organization with a large focus on CRDMO services and specialty ingredients across small molecules, peptides, fermentation and related modalities. What are the underlying business or industry changes driving this perspective?
544184
₹157.90
Borosil Scientific
7D
3.8%
1Y
-0.8%
DIVISLAB
₹8,056.00
Divi's Laboratories
7D
11.1%
1Y
26.6%
Narrative Update • Jul 23

DIVISLAB: Elevated Future P/E Will Continue To Signal Overvaluation Risk

Analysts have revised their price target for Divi's Laboratories to ₹5,610 from ₹5,333.98, citing updated assumptions for revenue growth, profit margins, and future P/E that collectively support a higher fair value estimate despite a slightly higher discount rate. What’s in the News for Divi's Laboratories A board meeting is scheduled on August 1, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.
524394
₹608.15
Vimta Labs
7D
6.6%
1Y
-11.7%
BROOKS
₹60.98
Brooks Laboratories
7D
-4.8%
1Y
-61.2%
511509
₹21.42
Vivo Bio Tech
7D
-6.7%
1Y
-35.5%
539267
₹10.64
Samsrita Labs
7D
-13.8%
1Y
-57.5%
AKUMS
₹658.35
Akums Drugs and Pharmaceuticals
7D
-4.2%
1Y
28.1%
Narrative Update • Jul 03

AKUMS: Upcoming Board Actions And Dividends Will Support Future Earnings Expansion

Analysts have lifted the fair value estimate for Akums Drugs and Pharmaceuticals from ₹646.67 to ₹730.00, citing updated assumptions around revenue growth, profit margins, a slightly altered discount rate, and future P/E. What’s in the News for Akums Drugs and Pharmaceuticals A board meeting is scheduled on May 14, 2026 to consider and approve the quarter and full year results for the period ended March 31, 2026, and to consider dividend recommendations, the appointment of Mahajan & Aibara LLP as Internal Auditors for FY 2026-27, and other matters.
DCAL
₹186.94
Dishman Carbogen Amcis
7D
1.8%
1Y
-23.6%
SAILIFE
₹1,315.10
Sai Life Sciences
7D
6.7%
1Y
66.9%
INNOVACAP
₹974.25
Innova Captab
7D
2.5%
1Y
9.7%
Narrative Update • Jun 26

INNOVACAP: Higher Fair Value And Governance Moves Will Support Bullish Re Rating

Analysts have revised their price target for Innova Captab to ₹1,078.50 from ₹891.50, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E as key inputs to the new valuation view. What’s in the News for Innova Captab The board has scheduled a meeting on May 25, 2026, to consider the reappointment of M/s.
526853
₹58.17
Bilcare
7D
-2.0%
1Y
-15.7%